Drug Repositioning for Effective Prostate Cancer Treatment.

摘要: Drug repositioning has gained attention from both academia and pharmaceutical companies as an auxiliary process to conventional drug discovery. Chemotherapeutic agents have notorious adverse effects that drastically reduce the life quality of cancer patients so is a promising strategy identify non-cancer drugs which anti-cancer activity well tolerable for human health. There are various strategies discovery validation repurposed drugs. In this review, 25 candidates presented result different strategies, 15 already under clinical investigation treatment prostate (PCa). To date, zoledronic acid only repurposed, clinically used, approved PCa. Anti-cancer activities existing in review cover diverse also known mechanisms such inhibition mTOR VEGFR2 signaling, PI3K/Akt COX selective COX-2 inhibition, NF-κB Wnt/β-Catenin pathway DNMT1 GSK-3β inhibition. addition monotherapy option, combination therapy with current may increase efficacy effects. Thus, become key approach terms time- cost-efficiency comparing development process.